CD44 Gene Polymorphisms on Hepatocellular Carcinoma Susceptibility and Clinicopathologic Features
Table 2
Distribution frequency of CD44 genotypes in 561 healthy controls and 203 patients with HCC.
Variable
Controls () (%)
Patients () (%)
OR (95% CI)
AOR (95% CI)
rs1425802
AA
194 (34.6%)
70 (34.5%)
1.00
1.00
AG
235 (41.9%)
75 (36.9%)
0.884 (0.607–1.290)
0.763 (0.487–1.194)
GG
132 (23.5%)
58 (28.6%)
1.218 (0.806–1.839)
1.071 (0.659–1.741)
AG+GG
367 (65.4%)
133 (65.5%)
1.004 (0.717–1.408)
0.878 (0.588–1.310)
rs187115
AA
403 (71.8%)
123 (60.6%)
1.00
1.00
AG
143 (25.5%)
66 (32.5%)
1.512 (1.061–2.156)*
1.488 (1.023–2.291)*
GG
15 (2.7%)
14 (6.9%)
3.058 (1.436–6.512)*
4.501 (1.687–12.012)*
AG+GG
158 (28.2%)
80 (39.4%)
1.659 (1.185–2.322)*
1.714 (1.139–2.579)*
rs713330
TT
467 (83.2%)
167 (82.3%)
1.00
1.00
TC
86 (15.4%)
36 (17.7%)
1.171 (0.764–1.795)
0.945 (0.564–1.585)
CC
8 (1.4%)
0 (0%)
—
—
TC+CC
94 (16.8%)
36 (17.7%)
1.071 (0.702–1.635)
0.897 (0.537–1.498)
rs11821102
GG
481 (85.7%)
173 (85.2%)
1.00
1.00
GA
75 (13.4%)
29 (14.3%)
1.075 (0.677–1.707)
1.126 (0.644–1.970)
AA
5 (0.9%)
1 (0.5%)
0.556 (0.065–4.793)
0.630 (0.064–6.165)
GA+AA
80 (14.3%)
30 (14.8%)
1.043 (0.662–1.642)
1.091 (0.631–1.885)
rs10836347
CC
487 (86.8%)
180 (88.7%)
1.00
1.00
CT
69 (12.3%)
23 (11.3%)
0.902 (0.546–1.490)
0.899 (0.494–1.634)
TT
5 (0.9%)
0 (0%)
—
—
CT+TT
74 (13.2%)
23 (11.3%)
0.841 (0.511–1.384)
0.872 (0.481–1.582)
rs13347
CC
295 (52.6%)
110 (54.2%)
1.00
1.00
CT
223 (39.8%)
72 (35.5%)
0.866 (0.614–1.222)
0.859 (0.568–1.300)
TT
43 (7.6%)
21 (10.3%)
1.310 (0.744–2.306)
1.357 (0.694–2.653)
CT+TT
266 (47.4%)
93 (45.8%)
0.938 (0.679–1.294)
0.944 (0.642–1.388)
The odds ratios (ORs) with their 95% confidence intervals (CIs) were estimated by logistic regression models. The adjusted odds ratios (AORs) with their 95% confidence intervals (CIs) were estimated by multiple logistic regression models after controlling for age and gender. * value < 0.05 is statistically significant.
